Since MGS is currently the only EMA approved therapy for the treatment of NPC1 disease, we therefore investigated if treatment with MGS gave rise to changes to the 1H NMR plasma metabolic profile of NPC1 patients. Here, NPC1 is linked to Niemann-Pick disease, type C1.